| |
|
|
|
|
|
|
|||
|
Blood, 1 December 2006, Vol. 108, No. 12, pp. 3801-3807. Prepublished online as a Blood First Edition Paper on August 15, 2006; DOI 10.1182/blood-2006-03-013235.
IMMUNOBIOLOGY Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infectionFrom the Department of Immunology, Wright Fleming Institute, and the Department of Genito-Urinary Medicine and Communicable Diseases, Imperial College London, United Kingdom; the Tumour Immunology Group, Weatherall Institute of Molecular Medicine, University of Oxford, United Kingdom; the Chemical Biology Program, Broad Institute of Harvard University and MIT, Cambridge, MA; and the Department of Immunology, Graduate School and Faculty of Medicine, University of the Ryukyus, Ryukyus, Japan.
The dynamics of human T-lymphotropic virus type-1 (HTLV-1) provirus expression in vivo are unknown. There is much evidence to suggest that HTLV-1 gene expression is restricted: this restricted gene expression may contribute to HTLV-1 persistence by limiting the ability of the HTLV-1specific CD8+ cell immune response to clear infected cells. In this study, we tested the hypothesis that derepression of HTLV-1 gene expression would allow an increase in CD8+ cellmediated lysis of HTLV-1infected cells. Using histone deacetylase enzyme inhibitors (HDIs) to hyperacetylate histones and increase HTLV-1 gene expression, we found that HDIs doubled Tax expression in naturally infected lymphocytes after overnight culture. However, the rate of CD8+ cellmediated lysis of Tax-expressing cells ex vivo was halved. HDIs appeared to inhibit the CD8+ cellmediated lytic process itself, indicating a role for the microtubule-associated HDAC6 enzyme. These observations indicate that HDIs may reduce the efficiency of cytotoxic T-cell (CTL) surveillance of HTLV-1 in vivo. The impact of HDIs on HTLV-1 proviral load in vivo cannot be accurately predicted because of the widespread effects of these drugs on cellular processes; we therefore recommend caution in the use of HDIs in nonmalignant cases of HTLV-1 infection.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||